Search results
Showing 1 to 14 of 14 results for haemophilia factor
In development [GID-TA11397] Expected publication date: 18 June 2025
Evidence-based recommendations on efanesoctocog alfa (Altuvoct) for treating and preventing bleeding episodes in haemophilia A in people 2 years and over.
Awaiting development [GID-TA11691] Expected publication date: TBC
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)
Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.
Evidence-based recommendations on interferon alfa (Pegasys or ViraferonPeg) and ribavirin for people with chronic hepatitis C.
New weekly treatment option approved for people with haemophilia B
Our final draft guidance published today recommends marstacimab (also called Hympavzi and made by Pfizer) for treating the severe form of blood disorder haemophilia B in people 12 years and over.
This guideline covers assessment and early management of head injury in babies, children, young people and adults. It aims to ensure that people have the right care for the severity of their head injury, including direct referral to specialist care if needed.
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
View recommendations for TA330Show all sections
SecurePort IV tissue adhesive for use with percutaneous catheters (MIB288)
NICE has developed a medtech innovation briefing (MIB) on SecurePort IV tissue adhesive for use with percutaneous catheters .
Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)
Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (also known as Viekirax) with or without dasabuvir (also known as Exviera) for adults with some types (called genotypes) of chronic hepatitis C.
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)
Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults.
The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)
NICE has developed a medtech innovation briefing (MIB) on the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies
Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)
Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C.
NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in people aged 2 and over with severe haemophilia A.